Predictive Value of CEA and ctDNA in Lung Cancer Recurrence

Predictive Value of CEA and ctDNA for Postoperative Recurrence in Patients With High CEA Sensitivity Lung Cancer

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07170046

Enrollment

100

Registered

2025-09-12

Start date

2025-09-15

Completion date

2027-08-01

Last updated

2025-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Carcinoma

Brief summary

The study aims to investigate the predictive value of CEA levels for postoperative recurrence in the highly sensitive CEA lung cancer patients and to explore whether the dynamic changes of postoperative CEA and MRD in this population are related.This study was carried out to accurately predict the recurrence time, save the time and cost of changing the intervention strategy, and provide more personalized treatment for patients.

Detailed description

This study will collect two groups of cohorts: prospective and retrospective.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

15 Years to 100 Years

Healthy volunteers

Inclusion criteria

1. Preoperative CEA \> 5mg/l 2. MRD testing was conducted before the operation 3. The primary lesion was resected through surgery 4. There should be at least two CEA and MRD follow-up tests within 2 years after the operation 5. Postoperative pathology confirmed it as a malignant lung tumor

Exclusion criteria

1. Those without available imaging records 2. Patients with a history of malignant tumors within the past five years 3. Patients with secondary lung cancer

Design outcomes

Primary

Measure	Time frame	Description
Postoperative tumor recurrence or progression	2 years	If the tumor recurs or progresses within 2 years, it will be marked as 1. If not, it will be marked as 0.

Outcome results